Page 7 - Acelyrin News Today

Acelyrin, Inc. (NASDAQ:SLRN – Get Rating) Director Beth C. Seidenberg acquired 60,000 shares of the firm’s stock in a transaction on Tuesday, May 9th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $1,080,000.00. Following the completion of the purchase, the director now directly owns 60,000 shares […]

Acelyrin, Inc. (NASDAQ:SLRN – Get Rating) major shareholder Biopartners Fund Ii Westlake acquired 1,250,000 shares of the stock in a transaction that occurred on Tuesday, May 9th. The stock was acquired at an average cost of $18.00 per share, with a total value of $22,500,000.00. Following the completion of the purchase, the insider now owns […]

Acelyrin, Inc. (NASDAQ:SLRN – Get Rating) Director Beth C. Seidenberg acquired 60,000 shares of the stock in a transaction dated Tuesday, May 9th. The shares were bought at an average cost of $18.00 per share, with a total value of $1,080,000.00. Following the transaction, the director now directly owns 60,000 shares of the company’s stock, […]

Acelyrin, Inc. (NASDAQ:SLRN – Get Rating) insider Ronald Oyston purchased 1,000 shares of the company’s stock in a transaction dated Tuesday, May 9th. The shares were acquired at an average price of $18.00 per share, with a total value of $18,000.00. Following the transaction, the insider now owns 1,000 shares in the company, valued at […]

LOS ANGELES, May 9, 2023 /PRNewswire/ -- ACELYRIN, INC. , a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology,... | May 9, 2023

Shares of Acelyrin Inc opened 28% above offering price in their market debut on Friday, giving the biopharma company a market capitalization of $2.1 billion. The Los Angeles-based... | May 5, 2023

Following is a summary of current health news briefs. US FDA declines to approve Ascendis' hormone disorder therapy Ascendis Pharma A/S said on Monday the U.S. Food & Drug Administration had declined to approve the Danish drugmaker's experimental therapy to treat adult patients with a hormone disorder called hypoparathyroidism, citing concerns linked to manufacturing control of the drug and device combination.

Biotech IPOs continues to be almost non-existent, but Acelyrin wants to see if the public markets have an appetite for its lead drug candidate. The small protein drug could match up favorably against blockbuster biologics and it has reached pivotal testing in three inflammatory disorders.

/PRNewswire/ -- ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in...

/PRNewswire/ -- ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in...